Long-Term Use of Controlled-Release Disopyramide in Patients with Severe Ventricular Arrhythmias

Paulk Jr., E. Alan
February 1987
Angiology;Feb1987 Part 2, Vol. 38, p198
Academic Journal
Controlled-release (CR) disopyramide phosphate has been available for the past four years for the management of patients with ventricular arrhythmias. The advantages of this preparation over the earlier form have for most patients been striking Improved patient compliance as regards dosing, ease in stabilizing blood levels of disopyramide, and effective antiarrhythmic control has been a significant factor in physician satisfaction with this preparation. Studies have demonstrated that effective blood levels are obtained with the 12-hour dosing schedule for controlled-release disopyramide phosphate in both normal volunteers and in patients with cardiac arrhythmias. Concern over the safety of disopyramide in patients with significant underlying heart disease, and especially in patients with a history of congestive heart failure, has been reported in a number of publications. No clinical observations are available in which patients with intractable ventricular arrhythmias have been managed with controlled-release disopyramide phosphate in addition to other appropriate therapy for their cardiac condition. Fifteen patients with significant left ventricular dysfunction were followed for an average of 20.6 months while receiving controlled-release disopyramide phosphate, and control of ventricular arrhythmias was achieved without worsening of left ventricular function.


Related Articles

  • Pharmacologic Evaluation of Standard and Controlled-Release Disopyramide. Siddoway, Lyle A.; Barbey, J. Toby; Roden, Dan M.; Woosley, Raymond L. // Angiology;Feb1987 Part 2, Vol. 38, p184 

    Controlled-release disopyramide offers many potential advantages over the standard formulation for improved patient compliance, possible reduction of concentration-related adverse effects, and predictability of pharmacologic effect. The pharmacology of disopyramide, potential advantages and...

  • Transfer from Immediate-Release Disopyramide to Controlled-Release Disopyramide. DiPersio, David M.; Chow, Moses S. S. // Angiology;Feb1987 Part 2, Vol. 38, p188 

    Simulation of serum disopyramide concentrations during transfer from steady-state immediate-release (IR) disopyramide to a sustained-release disopyramide preparation was performed based on pharmacokinetic parameters obtained from fit disopyramide and serum concentrations measured following an...

  • The Clinical Scope of Disopyramide Seven Years After Introduction -- An Overview. Willis III, Park W. // Angiology;Feb1987 Part 2, Vol. 38, p165 

    Disopyramide phosphate, seven years after its introduction, has proved to be a useful and effective Type IA oral agent for treatment of ventricular arrhythmias. The experience of these seven years has amplified and more sharply defined the initial efficiency and safety issues related to the use...

  • A Review of the Effects of Disopyramide Phosphate on Left Ventricular Function and the Peripheral Circulation. Di Bianco, Robert; Gottdiener, John S.; Singh, Steven N.; Fletcher, Ross D. // Angiology;Feb1987 Part 2, Vol. 38, p174 

    In the absence of preexistent myocardial dysfunction, the risk of producing cardiac decompensation in patients being treated with any of the conventional antiarrhythmic agents is low. The availability of disopyramide for clinical use in 1977 produced optimism for an effective antiarrhythmic...

  • The Pharmacokinetic and Pharmacodynamic Effects of Varying the Free Fraction of Disopyramide. Shaw, Leslie M.; Doherty, John U.; Waxman, Harvey L.; Josephson, Mark E. // Angiology;Feb1987 Part 2, Vol. 38, p192 

    We have evaluated the influence of several factors on the binding of disopyramide to protein in human serum using a new ultrafiltration system and the enzyme multiplied immunoassay technique (EMIT) for disopyramide immuno-assay. From these studies and those of other investigators, we conclude...

  • Enantioselective binding of disopyramide to α1-acid glycoprotein and its variants. Kishino, S.; Itoh, S.; Nakagawa, T.; Miyazaki, K. // European Journal of Clinical Pharmacology;Oct2001, Vol. 57 Issue 8, p583 

    Objective: α1-Acid glycoprotein (AAG) has three main genetic variants, F1, S, and A variants. There are few reports on the correlation between AAG variants and binding activity of drug enantiomers. We studied the differences between the binding characteristics of enantiomers of disopyramide...

  • Rythmodan Retard.  // Royal Society of Medicine: Medicines;2002, p483 

    The article presents information on rhythmodan retard, a proprietary, prescription-only preparation of the anti-arrhythmic disopyramide. It is available as modified-release tablets.

  • THE ELECTROPHYSIOLOGY OF NORPACE (PART III). Caracta, Anthony // Angiology;Jan1975 Part 2, Vol. 26, p120 

    Presents the electrophysiology of Norpace, an antiarrhythmic agents. Effects of disopyramide on the electrophysiological system of the A-V conducting system; Determination of the history of paroxysmal ventricular tachycardia; Mechanism of antiarrhythmic action.

  • Disopyramide Plasma Concentrations Following Single and Multiple Doses of the Immediate- and Controlled-Release Capsules. Karim, Aziz; Schubert, Elliot N.; Burns, Thomas S.; Palmer, Michael; Zinny, M. A. // Angiology;Jun1983, Vol. 34 Issue 6, p375 

    The article discusses disopyramide plasma concentrations following single and multiple doses of the immediate- and controlled-release capsules. Disopyramide phosphate is a type 1 antiarrhythmic drug used for suppression and prevention of recurrence of specific cardiac arrhythmias. It is freely...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics